Clinical Performance of a Phakic Intraocular Lens (IOL)

Presbyopia Clinical Trial

Official title:

A Multicenter Clinical Evaluation of the Clinical Performance of a Phakic Intraocular Lens

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03499821
• Other study ID #: Study CP17-01
• Status: Completed
• Phase: N/A
• Start date: March 20, 2018
• Est. completion date: July 9, 2019

Study information

• Verified date: May 2024
• Source: Staar Surgical Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the clinical performance of a phakic intraocular lens (IOL) for the improvement of Uncorrected Near Visual Acuity (UCNVA) in subjects who require between +1.00 and +2.50 Reading Add.

Description:

This is a prospective, open-labeled, multi-site evaluation of clinical performance of the STAAR EVO+ Visian™ Implantable Collamer® Lens (VICL) with Aspheric (EDOF) Optic [EDOF ICL] for the improvement of UCNVA in subjects who require between +1.00 and +2.50 Reading Add.

Approximately 48 subjects who meet all eligibility criteria will undergo EDOF ICL implantation in both eyes. All eyes will be followed for 6 months after surgery.

The first eye implanted with the study lens and the appropriate time for fellow eye implantation will be determined by the medical judgement of the Investigator. All eyes will be analyzed for safety and performance.

The primary performance endpoint is defined as achievement of monocular UCNVA of Snellen equivalent 20/40 or better at 40 cm at 6 months after implantation in equal to or greater than 75% of implanted eyes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: July 9, 2019
• Est. primary completion date: July 9, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Must be able to read, understand and provide written informed consent,

2. Willing and able to comply with all treatment and follow-up study related procedures,

3. 40 - 60 years of age at time of surgery if require spherical lens powers from -0.50 D to -18.00 D,

4. 35 - 45 years of age at time of surgery if require a spherical lens power from 0.0 D to +3.00 D,

5. Preoperative refraction fully correctable with available lens powers, with = 0.75 D preoperative refractive and residual cylinder,

6. < 0.75 D spherical equivalent difference between cycloplegic and manifest refractions,

7. Stable correction (± 0.50 D) as determined by manifest refraction spherical equivalent (MRSE),

8. Best Corrected Distance Visual Acuity 20/20 or better in both eyes,

9. Requires +1.00 D to +2.50 D reading add,

10. Anterior chamber depth (ACD) = 2.8 mm if require spherical lens powers from -0.50 D to -18.00 D,

11. ACD = 3.0 mm if require spherical lens powers from 0.00 D to +3.00 D,

12. Anterior chamber angle = Grade III,

13. Phakic in both eyes,

14. Current contact lens wearers need to demonstrate a stable refraction, (± 0.5 D), expressed as MRSE, on two consecutive examination dates with refractive stability determined by the following criteria:

1. contact lenses were not worn for at least 2 weeks (rigid and toric contact lenses) or 3 days (soft contact lenses) prior to the first refraction,

2. two refractions were performed at least 7 days apart.

Exclusion Criteria:

1. Participation in a clinical trial within 30 days prior to entry into this study and/or during the period of study participation,

2. Previous intraocular or corneal surgery in either eye, including refractive surgery,

3. Progressive sight threatening disease or other previous or current ocular conditions, other than myopia in either eye,

4. Low/abnormal corneal endothelial cell density,

5. Amblyopia,

6. Presence of active or history of chronic inflammation in either eye,

7. Clinically significant irregular astigmatism in either eye,

8. Serious, acute, chronic or systemic, non-ophthalmic disease or illness that would increase the operative risk, confound the outcome(s) of the study or which may preclude study completion,

9. Use of topical steroids at time of implantation,

10. Systemic or topical medication, other than prescribed study medications that may confound the outcome or increase the risk to the subject,

11. Allergy to anesthetics or other postoperative medications required in this study,

12. Subject who is pregnant, plans to become pregnant, or is lactating during the course of the study, or has another condition associated with the fluctuation of hormones that could lead to refractive changes,

13. Subjects who present any emotional, physiologic, or anatomical condition which may preclude study participation.

Related Conditions & MeSH terms

• Presbyopia

Intervention

Device:
• EDOF ICL
The Visian ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens. It offers an intraocular alternative for the correction of refractive error in those who currently utilize spectacle and/or contact lenses correction.

Locations

Country	Name	City	State
Belgium	Mediopolis	Antwerp
Spain	Qvision-Hospital Vithas Virgen del Mar	Almería
Spain	IMO Instituto de Microcirugía Ocular	Barcelona
Spain	Instituto Oftalmológico Fernández-Vega	Oviedo	Asturias
Spain	Innova Ocular Begitek	San Sebastián
Spain	Clínica Oftalmológica Gasteiz	Vitoria-Gasteiz

Sponsors (1)

Lead Sponsor	Collaborator
Staar Surgical Company

Countries where clinical trial is conducted

Belgium,  Spain, 

References & Publications (1)

Packer M, Alfonso JF, Aramberri J, Elies D, Fernandez J, Mertens E. Performance and Safety of the Extended Depth of Focus Implantable Collamer(R) Lens (EDOF ICL) in Phakic Subjects with Presbyopia. Clin Ophthalmol. 2020 Sep 18;14:2717-2730. doi: 10.2147/O — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Eyes With Monocular Uncorrected Near Visual Acuity of 20/40 or Better at 40 cm 6 Months After Implantation	Number of Eyes with Monocular Uncorrected Near Visual Acuity of 20/40 or better at 40 cm six months after implantation	6 months
Secondary	Percentage of Implanted Eyes Achieving Monocular Uncorrected Near Visual Acuity of 20/40 or Better at 40 cm 1 Month After Implantation	Percentage of implanted eyes achieving Monocular Uncorrected Near Visual Acuity (UNVA) of 20/40 or better at 40 cm 1 month after implantation	1 month
Secondary	Percentage of Implanted Eyes Achieving Monocular Uncorrected Near Visual Acuity of 20/40 or Better at 40 cm 3 Months After Implantation	Percentage of implanted eyes achieving Monocular Uncorrected Near Visual Acuity (UNVA) of 20/40 or better at 40 cm 3 months after implantation	3 months
Secondary	Change From Baseline in Monocular Uncorrected Intermediate Visual Acuity at 80 cm 1 Month Post Implantation	Change from baseline in Monocular Uncorrected Intermediate Visual Acuity (UIVA) at 80 cm 1 month post implantation	Baseline and 1 month
Secondary	Change From Baseline in Monocular Uncorrected Intermediate Visual Acuity at 80 cm 3 Months Post Implantation	Change from baseline in Monocular Uncorrected Intermediate Visual Acuity (UIVA) at 80 cm 3 months post implantation	Baseline and 3 months
Secondary	Change From Baseline in Monocular Uncorrected Intermediate Visual Acuity at 80 cm 6 Months Post Implantation	Change from baseline in Monocular Uncorrected Intermediate Visual Acuity (UIVA) at 80 cm 6 months post implantation	Baseline and 6 months
Secondary	Change From Baseline in Monocular Uncorrected Near Visual Acuity at 40 cm 1 Month Post Implantation	Change from baseline in Monocular Uncorrected Near Visual Acuity (UNVA) at 40 cm 1 month post implantation	Baseline and 1 month
Secondary	Change From Baseline in Monocular Uncorrected Near Visual Acuity at 40 cm 3 Months Post Implantation	Change from baseline in Monocular Uncorrected Near Visual Acuity (UNVA) at 40 cm 3 months post implantation	Baseline and 3 months
Secondary	Change From Baseline in Monocular Uncorrected Near Visual Acuity at 40 cm 6 Months Post Implantation	Change from baseline in Monocular Uncorrected Near Visual Acuity (UNVA) at 40 cm 6 months post implantation	Baseline and 6 months
Secondary	Change From Baseline in Monocular Distance Corrected Intermediate Visual Acuity at 80 cm 1 Month Post Implantation	Change from baseline in Monocular Distance Corrected Intermediate Visual Acuity (DCIVA) at 80 cm 1 month post implantation	Baseline and 1 month
Secondary	Change From Baseline in Monocular Distance Corrected Intermediate Visual Acuity at 80 cm 3 Months Post Implantation	Change from baseline in Monocular Distance Corrected Intermediate Visual Acuity (DCIVA) at 80 cm 3 months post implantation	Baseline and 3 months
Secondary	Change From Baseline in Monocular Distance Corrected Intermediate Visual Acuity at 80 cm 6 Months Post Implantation	Change from baseline in Monocular Distance corrected intermediate visual acuity (DCIVA) at 80 cm 6 months post implantation	Baseline and 6 months
Secondary	Change From Baseline in Monocular Distance Corrected Near Visual Acuity at 40 cm 1 Month Post Implantation	Change from baseline in Monocular Distance Corrected Near Visual Acuity (DCNVA) at 40 cm 1 month post implantation	Baseline and 1 month
Secondary	Change From Baseline in Monocular Distance Corrected Near Visual Acuity at 40 cm 3 Months Post Implantation	Change from baseline in Monocular Distance Corrected Near Visual Acuity (DCNVA) at 40 cm 3 months post implantation	Baseline and 3 months
Secondary	Change From Baseline in Monocular Distance Corrected Near Visual Acuity at 40 cm 6 Months Post Implantation	Change from baseline in Monocular Distance Corrected Near Visual Acuity (DCNVA) at 40 cm 6 months post implantation	Baseline and 6 months
Secondary	Change From Baseline in Binocular Uncorrected Near Visual Acuity at 40 cm 1 Month Post Implantation	Change from baseline in Binocular Uncorrected Near Visual Acuity (UNVA) at 40 cm 1 month post implantation	Baseline and 1 month
Secondary	Change From Baseline in Binocular Uncorrected Near Visual Acuity at 40 cm 3 Months Post Implantation	Change from baseline in Binocular Uncorrected Near Visual Acuity (UNVA) at 40 cm 3 months post implantation	Baseline and 3 months
Secondary	Change From Baseline in Binocular Uncorrected Near Visual Acuity at 40 cm 6 Months Post Implantation	Change from baseline in Binocular Uncorrected Near Visual Acuity (UCNVA) at 40 cm 6 months post implantation	Baseline and 6 months